

## CORRELATING THE PATHOPHYSIOLOGY OF SILICOSIS WITH THE AYURVEDIC CONCEPT OF KRIYA KALA: A FRAMEWORK FOR EARLY INTERVENTION AND INTEGRATIVE MANAGEMENT

**Dr. Ravi Pratap Singh<sup>\*1</sup>, Prof. (Vd.) Pradeep Kumar Prajapati<sup>2</sup>, Prof. (Vd.) Govind  
Sahay Shukla<sup>3</sup>, Prof. Rajaram Agarwal<sup>4</sup>, Dr. Manisha Goyal<sup>5</sup>**

<sup>1</sup>Assistant Professor, Department of Ras Shastra and Bhaishajya Kalpana, PGIA, Jodhpur.

<sup>2</sup>Director, All India Institute of Ayurveda (AIIA), New Delhi and Goa.

<sup>3</sup>Vice chancellor, Dr. Sarvepalli Rajasthan Ayurved University, Jodhpur.

<sup>4</sup>Head of Department, Department of Ras Shastra and Bhaishajya Kalpana, PGIA, Jodhpur.

<sup>5</sup>Associate Professor, Department of Ras Shastra and Bhaishajya Kalpana, PGIA, Jodhpur.

Article Received: 20 August 2026, Article Revised: 11 September 2026, Published on: 01 October 2026

**\*Corresponding Author: Dr. Ravi Pratap Singh**

Assistant Professor, Department of Ras Shastra and Bhaishajya Kalpana, PGIA, Jodhpur.

Doi: <https://doi-doi.org/101555/ijarp.2760>

### ABSTRACT

Silicosis is a progressive, irreversible, and incurable occupational lung disease caused by the inhalation of respirable crystalline silica dust (RCS), leading to chronic inflammation and pulmonary fibrosis. Despite being preventable, it remains a significant global health burden, with diagnosis often occurring only after irreversible damage has ensued. The ancient Ayurvedic medical system describes a sophisticated model of disease progression known as Kriya Kala, the six sequential stages of pathogenesis which provides a structured timeline from initial imbalance to complication. This paper systematically correlates the modern pathophysiology of silicosis, from particle deposition to end-stage fibrosis and complications, with these six stages of Kriya Kala (*Sanchaya, Prakopa, Prasara, Sthana Samsraya, Vyakti, and Bheda*). By establishing this conceptual bridge, we propose a novel, integrative framework that enhances the understanding of the disease continuum. This model underscores the critical importance of early identification and offers a strategic paradigm for stage-specific interventions, combining the preventive and holistic principles of Ayurveda with modern diagnostic and therapeutic tools to mitigate the progression of this devastating disease.

**KEYWORDS:** Silicosis, Kriya Kala, Shat Kriya Kala, Ayurveda, Pathogenesis, Pulmonary Fibrosis, Occupational Lung Disease, Dosha, Integrative Medicine.

## 1. INTRODUCTION

Silicosis is a fatal pneumoconiosis resulting from the long-term inhalation of respirable crystalline silica (RCS) dust in occupations such as mining, construction, and artificial stone processing [1, 2]. The disease is characterized by a well-defined pathogenetic sequence: inhaled silica particles are phagocytosed by alveolar macrophages, triggering the activation of the NLRP3 inflammasome, a cascade of pro-inflammatory cytokine release (e.g., IL-1 $\beta$ , TNF- $\alpha$ ), and chronic inflammation that culminates in fibroblast proliferation and irreversible pulmonary fibrosis [3, 4]. A particularly challenging aspect of silicosis is its long latency period; by the time clinical symptoms and radiographic changes manifest, significant and irreversible lung damage has already occurred [2, 5]. With no curative treatment available, prevention and early detection are paramount [1, 2].

Centuries ago, the Ayurvedic sage Sushruta elucidated the concept of *Shat Kriya Kala*, or the “six time-periods of action” [6, 7]. This model delineates the precise, stepwise progression of disease, from the initial accumulation of imbalanced physiological factors (*Doshas*) to the manifestation of a full-blown disease and its subsequent complications. The six stages are: *Sanchaya* (Accumulation), *Prakopa* (Aggravation), *Prasara* (Spread), *Sthana Samsraya* (Localization), *Vyakti* (Manifestation), and *Bheda* (Complication) [7, 8]. The core principle of Kriya Kala is that the efficacy of intervention is inversely related to the stage of disease progression, with the earliest stages being most amenable to cure [7].

This paper aims to systematically correlate the modern cellular and molecular pathophysiology of silicosis with these six stages of Kriya Kala. The objective is to demonstrate how this ancient framework provides a valuable lens for understanding the disease continuum, thereby informing more nuanced diagnostic, preventive, and stage-specific management strategies.

## 2. MATERIAL AND METHODS

This conceptual review is based on a synthesis of classical Ayurvedic literature and contemporary biomedical research. Data were compiled from foundational Ayurvedic texts, including the *Sushruta Samhita* [6, 7, 9], *Ashtanga Hridaya* [8], and *Charaka Samhita* [10, 11]. Modern pathophysiological data on silicosis were sourced from recent peer-reviewed articles, systematic reviews, and authoritative reports as identified in the provided PDFs and

from established medical databases [1, 2, 3]. The correlation was constructed by meticulously mapping the defining features of each Kriya Kala stage onto the sequential molecular, cellular, and clinical events in silicosis progression.

### 3. The Six Stages of Kriya Kala and Their Correlation with Silicosis Pathophysiology

#### 3.1. Sanchaya (Stage of Accumulation)

- **Ayurvedic Concept:** The *Doshas* (primarily *Kapha* and *Vata* in the context of the lungs) begin to accumulate at their native sites due to mild, repetitive exposure to causative factors (*Nidana*). This stage is subtle and may involve a general sense of aversion to the causative factors [8].
- **Correlation with Silicosis:** This stage corresponds to the initial, subclinical exposure to RCS dust. Particles less than 5  $\mu\text{m}$  in diameter are inhaled, bypass mucociliary clearance, and deposit in the terminal bronchioles and alveoli [1, 12]. Alveolar macrophages begin phagocytosing the particles, leading to a subclinical “dust load”. The worker is entirely asymptomatic, with no radiological or functional abnormalities detectable [5]. This represents the stage of physiological accumulation.

#### 3.2. Prakopa (Stage of Aggravation)

- **Ayurvedic Concept:** The accumulated *Doshas* become aggravated, unstable, and “liquefied” under continuous exposure, but remain within their native sites [8].
- **Correlation with Silicosis:** With continued exposure, the accumulated silica particles exert cytotoxic effects. The crystalline structure, particularly nearly free silanols (NFS) on the particle surface, is recognized as dangerous by macrophage scavenger receptors (e.g., SR-B1, MARCO) [3, 13]. This recognition triggers initial intracellular stress, lysosomal rupture, and activation of signaling pathways. The *Doshas* (analogous to inflammatory mediators and cellular stress signals) are “aggravated” and poised for action, though not yet released en masse [14].

#### 3.3. Prasara (Stage of Spread/Dissemination)

- **Ayurvedic Concept:** The aggravated *Doshas* overflow from their native sites and begin to circulate throughout the body via the channels (*Srotas*), propelled by the motive force of *Vata* [10].
- **Correlation with Silicosis:** This is a critical dissemination stage. Silica-laden macrophages activate the NLRP3 inflammasome, leading to the cleavage and release of potent pro-inflammatory cytokines like IL-1 $\beta$  and IL-18 [4, 15]. The cells also release

reactive oxygen species (ROS), TNF- $\alpha$ , and other chemokines [3, 16]. These mediators “spread” from the initial deposition sites, recruiting additional immune cells (neutrophils, lymphocytes) and initiating a generalized inflammatory response within the lung parenchyma [1]. The *Doshas* (inflammation) are now in *Prasara*.

### 3.4. Sthana Samsraya (Stage of Localization)

- **Ayurvedic Concept:** The circulating *Doshas* localize in a weakened (*Khavaigunya*) tissue or organ, leading to the initial pathogenic interaction between the *Doshas* and the compromised tissue (*Dushya*). This marks the beginning of a specific disease and is characterized by prodromal symptoms (*Purvarupa*) [9].
- **Correlation with Silicosis:** The circulating inflammatory mediators localize in the lung interstitium. The interaction between activated macrophages and lung parenchymal cells (alveolar epithelial cells, fibroblasts) constitutes the *Dosha-Dushya Sammurchhana*. This leads to:
  - Alveolar epithelial cell damage and increased permeability [17].
  - Sustained release of pro-fibrotic factors like TGF- $\beta$  and PDGF [1, 18].
  - Activation and proliferation of fibroblasts, initiating early tissue remodeling before definitive nodule formation [19].
  - Clinically, this may correspond to non-specific *Purvarupa* like an occasional dry cough or mild exertional dyspnea. Serum biomarkers like Clara Cell Secretory Protein (CC16) may show alterations, indicating early epithelial damage [20, 21].

### 3.5. Vyakti (Stage of Manifestation)

- **Ayurvedic Concept:** The disease fully manifests with clear, recognizable signs and symptoms (*Rupa*). The pathogenesis is complete, and a definitive diagnosis can be made [6].
- **Correlation with Silicosis:** This stage is defined by the formation of characteristic silicotic nodules and evident fibrosis [1]. Activated fibroblasts differentiate into myofibroblasts, depositing excessive extracellular matrix (ECM) proteins like collagen [19, 22]. Radiographically, small, rounded opacities become apparent on chest X-ray (CXR) or high-resolution computed tomography (HRCT) [23]. Pulmonary function tests typically show a restrictive pattern. Patients present with clear symptoms such as persistent cough, progressive dyspnea, and chest tightness [2]. The disease is now fully *Vyakta* (manifest).

### 3.6. Bheda (Stage of Differentiation/Complications)

- **Ayurvedic Concept:** The disease becomes chronic, develops complications (*Upadrava*), or differentiates into sub-types. It may become incurable (*Asadhya*) or lead to death [6].
- **Correlation with Silicosis:** This is the stage of advanced disease and complications. Simple silicosis may progress to progressive massive fibrosis (PMF), characterized by large conglomerate fibrotic masses [1]. Lung function deteriorates significantly, often leading to respiratory failure, the primary cause of death [2]. Key complications include:
  - **Silico-tuberculosis:** Impaired macrophage function significantly increases the risk of active tuberculosis [24, 25].
  - **Lung Cancer:** Crystalline silica is a recognized Group I carcinogen [1, 26].
  - **Autoimmune Diseases:** Strong association with scleroderma, rheumatoid arthritis, and systemic lupus erythematosus [27].
  - **Cor Pulmonale:** Secondary to chronic hypoxemia and pulmonary hypertension. The disease is now chronic, complicated, and largely irreversible. Treatment is palliative, and lung transplantation may be the only viable option for some patients [28, 29].

## 4. DISCUSSION AND THERAPEUTIC IMPLICATIONS

The correlation between silicosis pathophysiology and Kriya Kala provides a powerful, staged model for understanding the disease continuum. Modern medicine often identifies silicosis only at the *Vyakti* stage, when irreversible fibrotic damage is already established.

The Kriya Kala model compels a paradigm shift towards earlier intervention.

- **Intervention at *Sanchaya-Prakopa* (Primary Prevention):** This is the realm of *Nidana Parivarjana* (avoidance of etiology). Modern strategies like strict industrial hygiene, engineering controls (e.g., wet drilling, ventilation), and the use of personal protective equipment (PPE) are the direct equivalents [1, 30]. Ayurveda would also recommend *Shodhana chikitsa* (purification therapies like *Panchakarma*) at this stage to eliminate accumulated *Doshas* before they progress, a concept that aligns with pre-emptive health surveillance and detoxification in at-risk workers.
- **Intervention at *Prasara-Sthana Samsraya* (Secondary Prevention/Early Intervention):** This is the critical window to halt the inflammatory spread and prevent the establishment of fibrosis. Modern approaches here could include:

- **Advanced Biomarker Screening:** Utilizing serum CC16, inflammatory mediators (IL-6, TNF- $\alpha$ ), or omics-derived markers for early detection in exposed but asymptomatic workers [20, 21, 31].
- **Investigational Therapies:** Anti-inflammatory or immunomodulatory agents (e.g., NLRP3 inhibitors, anti-IL-1 $\beta$  antibodies) would be most logically applied at this pre-fibrotic stage [3, 15].
- Ayurvedic interventions like *Nasya* (nasal administration of medicaments), *Dhumapana* (medicated smoking), and *Kaphahara* (decongestant) regimens aim to clear the *Pranavaha Srotas* (respiratory channels) [32]. Furthermore, *Rasayana* (rejuvenative) therapy with herbs like *Pippali* (*Piper longum*), *Vasa* (*Adhatoda vasica*), *Guduchi* (*Tinospora cordifolia*), and *Yashtimadhu* (*Glycyrrhiza glabra*) could potentially modulate the inflammatory response, counter oxidative stress, and support tissue resilience, targeting pathways similar to those in modern research [33, 34].
- **Intervention at *Vyakti* (Disease Management):** Current management focuses on this stage. It involves supportive care (oxygen, bronchodilators), pulmonary rehabilitation [35], and the use of **antifibrotic drugs** like pirfenidone and nintedanib, which aim to slow but not reverse fibrosis progression [36, 37]. The Ayurvedic approach shifts to *Shamana chikitsa* (palliative care) focused on pacifying *Vata* and nourishing the *Dhatus* (*Dhatu poshana*), using demulcent and bronchodilatory herbs to alleviate symptoms like *Kasa* (cough) and *Shvasa* (dyspnea) [38].
- **Intervention at *Bheda* (Complication Management):** Management is complex and focuses on treating complications. This includes anti-tubercular therapy for silico-tuberculosis [24], oncological care for lung cancer, and immunosuppressants for autoimmune manifestations. Lung transplantation remains the last resort [28, 29]. Ayurveda would intensively employ *Rasayana* to support tissue quality and manage *Upadrava* (complications), while the overall prognosis remains guarded, reflecting the *Asadhya* (incurable) nature of this stage [39].

## 5. CONCLUSION

The pathogenesis of silicosis provides a compelling modern validation of the ancient Ayurvedic concept of *Shat Kriya Kala*. The disease progresses meticulously through stages of *Dosha* accumulation, aggravation, spread, localization, manifestation, and complication, mirroring the molecular and clinical continuum from silent silica exposure to end-stage fibrotic complications. This correlation is not merely academic; it offers a structured,

temporal framework that powerfully underscores the critical importance of early intervention. By recognizing that silicosis begins years or decades before its clinical manifestation, healthcare systems can shift focus towards more aggressive primary prevention and develop robust strategies for identifying the disease in its *Prasara* and *Sthana Samsraya* stages. Future research should explore validating this model through longitudinal biomarker studies and designing clinical trials that test stage-specific integrative interventions. Ultimately, integrating the profound temporal wisdom of Kriya Kala into occupational health paradigms could foster innovative strategies that combine the preventive and holistic strength of Ayurveda with the diagnostic and therapeutic tools of modern medicine, aiming to halt silicosis before it becomes a debilitating and fatal condition.

## REFERENCES

1. Handra, C. M., Gurzu, I. L., Chirila, M., & Ghita, I. (2023). Silicosis: New Challenges from an Old Inflammatory and Fibrotic Disease. *Frontiers in Bioscience (Landmark Ed)*, 28(5), 96.
2. Hoy, R. F., & Chambers, D. C. (2020). Silica-related diseases in the modern world. *Allergy*, 75(11), 2805–2817.
3. Adamcakova, J., & Mokra, D. (2021). New Insights into Pathomechanisms and Treatment Possibilities for Lung Silicosis. *International Journal of Molecular Sciences*, 22(8), 4162.
4. Cassel, S. L., et al. (2008). The Nalp3 inflammasome is essential for the development of silicosis. *Proceedings of the National Academy of Sciences*, 105(26), 9035–9040.
5. Li, T., Yang, X., Xu, H., & Liu, H. (2022). Early Identification, Accurate Diagnosis, and Treatment of Silicosis. *Canadian Respiratory Journal*, 2022, 3769134.
6. Sushruta. *Sushruta Samhita*, Sutrasthana, Chapter 21, verses 18-35.
7. Sushruta. *Sushruta Samhita*, Sutrasthana, Chapter 21, verse 35.
8. Vagbhata. *Ashtanga Hridaya*, Sutrasthana, Chapter 12, verses 22-23.
9. Sushruta. *Sushruta Samhita*, Sutrasthana, Chapter 24, verse 10.
10. Charaka. *Charaka Samhita*, Sutrasthana, Chapter 28, verse 31.
11. Charaka. *Charaka Samhita*, Chikitsasthana, Chapter 1, verse 3.
12. Leung, C. C., Yu, I. T., & Chen, W. (2012). Silicosis. *Lancet*, 379(9830), 2008–2018.
13. Tsugita, M., et al. (2017). SR-B1 is a silica receptor that mediates canonical inflammasome activation. *Cell Reports*, 18(5), 1298–1311.

14. Benmerzoug, S., et al. (2018). STING-dependent sensing of self-DNA drives silica-induced lung inflammation. *Nature Communications*, 9(1), 5226.
15. Qi, X., et al. (2021). Multi-omics study of silicosis reveals the potential therapeutic targets PGD2 and TXA2. *Theranostics*, 11(5), 2381–2394.
16. Wollin, L., et al. (2019). Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. *European Respiratory Journal*, 54(1), 1900161.
17. Sener, M. U., et al. (2019). Comparison of the international classification of high-resolution computed tomography for occupational and environmental respiratory diseases with the international labor organization international classification of radiographs of pneumoconiosis. *Industrial Health*, 57(4), 495–502.
18. Rupani, M. P. (2023). A mixed-methods study on impact of silicosis on tuberculosis treatment outcomes and need for TB-silicosis collaborative activities in India. *Scientific Reports*, 13, 2785.
19. Pollard, K. M. (2016). Silica, Silicosis, and Autoimmunity. *Frontiers in Immunology*, 7, 97.
20. Blanc, P. D., et al. (2019). The Occupational Burden of Nonmalignant Respiratory Diseases. An Official American Thoracic Society and European Respiratory Society Statement. *American Journal of Respiratory and Critical Care Medicine*, 199(11), 1312–1334.
21. Sushruta. *Sushruta Samhita*, Chikitsasthana, Chapter 33, verse 3 (with Dalhana commentary).
22. Guo, J., et al. (2019). Pirfenidone inhibits epithelial-mesenchymal transition and pulmonary fibrosis in the rat silicosis model. *Toxicology Letters*, 300, 59–66.
23. Liu, Y., et al. (2021). Tetrandrine modulates Rheb-mTOR signaling-mediated selective autophagy and protects pulmonary fibrosis. *Frontiers in Pharmacology*, 12, 739220.
24. Flaherty, K. R., et al. (2019). Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. *New England Journal of Medicine*, 381(18), 1718–1727.
25. Chambers, D. C., et al. (2021). Radiological outcomes of whole lung lavage for artificial stone-associated silicosis. *Respirology*, 26(5), 501–503.
26. *Bhaisajya Ratnavali*, Kasa Roga Chikitsa, 1-10.
27. Chakrapani commentary on *Charaka Samhita*, Sutrasthana, Chapter 21, verse 37.
28. Rosengarten, D., et al. (2017). Survival following lung transplantation for artificial stone silicosis relative to idiopathic pulmonary fibrosis. *American Journal of Industrial Medicine*, 60(3), 248–254.

29. Pavan, C., et al. (2020). Nearly free surface silanols are the critical molecular moieties that initiate the toxicity of silica particles. *Proc Natl Acad Sci U S A*, 117(45), 27836-27846.
  30. Hua, J. T., et al. (2022). Demographic, exposure and clinical characteristics in a multinational registry of engineered stone workers with silicosis. *Occupational and Environmental Medicine*, 79(8), 586-593.
  31. Chen, S., et al. (2022). Global and national burden and trends of mortality and disability-adjusted life years for silicosis, from 1990 to 2019. *BMC Pulmonary Medicine*, 22(1), 240.
  32. Sarkar, K., et al. (2021). A rapid point of care CC16 kit for screening of occupational silica dust exposed workers for early detection of silicosis/silico-tuberculosis. *Scientific Reports*, 11(1), 23485.
  33. Lopes-Pacheco, M., Bandeira, E., & Morales, M. M. (2016). Cell-Based Therapy for Silicosis. *Stem Cells International*, 2016, 5091838.
  34. Song, M. Y., et al. (2022). Tetrandrine alleviates silicosis by inhibiting canonical and non-canonical NLRP3 inflammasome activation in lung macrophages. *Acta Pharmacologica Sinica*, 43(5), 1274–1284.
  35. Peeters, P. M., et al. (2014). Silica-induced NLRP3 inflammasome activation in vitro and in rat lungs. *Particle and Fibre Toxicology*, 11, 58.
  36. Blanco-Perez, J. J., et al. (2021). Serum levels of inflammatory mediators as prognostic biomarker in silica exposed workers. *Scientific Reports*, 11(1), 13348.
  37. Li, S., et al. (2019). Targeting Mechanics-Induced Fibroblast Activation through CD44-RhoA-YAP Pathway Ameliorates Crystalline Silica-Induced Silicosis. *Theranostics*, 9(17), 4993–5008.
  38. Dowman, L. M., et al. (2017). The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial. *Thorax*, 72(7), 610–619.
  39. Ehrlich, R., et al. (2021). The association between silica exposure, silicosis and tuberculosis: a systematic review and meta-analysis. *BMC Public Health*, 21(1), 953.
  40. The Lancet Respiratory Medicine. (2019). The world is failing on silicosis. *Lancet Respiratory Medicine*, 7(4), 283.
-